

## Genome-wide association study of the rate of cognitive decline in Alzheimer's disease

Richard Sherva<sup>a</sup>, Yorghos Tripodis<sup>b</sup>, David A. Bennett<sup>c</sup>, Lori B. Chibnik<sup>d,e,f</sup>, Paul K. Crane<sup>g</sup>, Philip L. de Jager<sup>d,e,f</sup>, Lindsay A. Farrer<sup>a,b,h</sup>, Andrew J. Saykin<sup>i</sup>, Joshua M. Shulman<sup>j</sup>, Adam Naj<sup>k</sup>, Robert C. Green<sup>l,\*</sup>, The GENAROAD Consortium, The Alzheimer's Disease Neuroimaging Initiative, and The Alzheimer's Disease Genetics Consortium

<sup>a</sup>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA, USA

<sup>b</sup>Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA

<sup>c</sup>Rush Alzheimer's Disease Center, Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA

<sup>d</sup>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology & Psychiatry, Brigham and Women's Hospital Boston, MA, USA

<sup>e</sup>Department of Neurology, Harvard Medical School, Cambridge, MA, USA

<sup>f</sup>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA

<sup>g</sup>School of Medicine, University of Washington, Seattle, WA, USA

<sup>h</sup>Departments Ophthalmology, Neurology, and Epidemiology, Boston University Schools of Medicine and Public Health, Boston, MA, USA

<sup>i</sup>Department of Medical and Molecular Genetics, Center for Neuroimaging, Department of Radiology and Imaging Sciences, Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA

<sup>j</sup>Departments of Neurology and Molecular and Human Genetics Baylor College of Medicine Jan and Dan Duncan Neurological Research Institute, Houston, TX, USA

<sup>k</sup>Department of Biostatics and Epidemiology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA

<sup>l</sup>Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

### Abstract

**Background:** Substantial interindividual variability exists in the disease trajectories of Alzheimer's disease (AD) patients. Some decline rapidly whereas others decline slowly, and there are no known explanations for this variability. We describe the first genome-wide association study to examine rate of cognitive decline in a sample of AD patients with longitudinal measures of cognition.

**Methods:** The discovery sample was 303 AD cases recruited in the Alzheimer's Disease Neuroimaging Initiative and the replication sample was 323 AD cases from the Religious Orders Study and Rush Memory and Aging Project. In the discovery sample, Alzheimer's Disease Assessment Scale–cognitive subscale responses were tested for association with genome-wide single-nucleotide polymorphism (SNP) data using linear regression. We tested the 65 most significant SNPs from the discovery sample for association in the replication sample.

**Results:** We identified SNPs in the spondin 1 gene (*SPON1*), the minor alleles of which were significantly associated with a slower rate of decline (rs11023139,  $P = 7.0 \times 10^{-11}$ ) in the discovery sample. A *SPON1* SNP 5.5 kb upstream was associated with decline in the replication sample (rs11606345,  $P = .002$ ).

**Conclusion:** *SPON1* has not been previously associated with AD risk, but is plausibly related because the gene product binds to the amyloid precursor protein and inhibits its cleavage by  $\beta$ -secretase. These data suggest that *SPON1* may be associated with the differential rate of cognitive decline in AD. © 2014 The Alzheimer's Association. All rights reserved.

### Keywords:

Alzheimer's disease; GWAS; Cognitive decline

### 1. Introduction

Alzheimer's disease (AD) is a common form of dementia with an enormous public health impact and for which

\*Corresponding author. Tel.: 617-264-5834; Fax: 617-264-3018.  
E-mail address: rcgreen@genetics.med.harvard.edu

there are no treatments yet available to slow progression. Through the efforts of large consortia that pool data from many genome-wide association studies (GWAS) of late-onset AD, several risk genes have been identified and robustly replicated [1–5]. Only with samples in excess of 10,000 AD cases and similar numbers of controls has consensus been reached on the veracity of these risk variants, and with the exception of the *APOE*  $\epsilon$ 4 allele, these variants exert very modest effects on overall disease risk, generally with odds ratios less than 1.2. Although these findings have provided valuable insights into AD pathogenesis, the individual predictive value of these small-effect variants is limited.

Although AD is characterized by progressive cognitive deterioration over time, substantial variability exists in the cognitive trajectories of affected individuals. There have been several previous studies of factors reported to be associated with cognitive decline in AD patients that have not examined genetic factors. One suggests that the pathological findings such as neurofibrillary tangles, cerebral infarction, and Lewy bodies that mediate normal and pathological age-related cognitive decline also mediate more rapid cognitive decline in some AD patients [6]. Other reports have postulated superimposed medical factors to be associated with rate of decline in AD, including diabetes [7] and other vascular risk factors [8], kidney function [9], and muscle strength [10]. Two recent candidate gene studies [11,12] tested a limited number of candidate single-nucleotide polymorphisms (SNPs) for association with rate of decline and identified some promising associations.

In this report, we present the first genome-wide association analysis of cognitive decline in a sample of AD cases with longitudinal measures of cognition. By limiting the analysis to AD cases, we hoped to identify novel variants specific to rate of decline. Although identifying variants explaining the heterogeneity in rate of decline is important for understanding AD pathogenesis, it may also produce novel therapeutic targets that are distinct from those associated with the presence or absence of AD.

## 2. Methods

### 2.1. Discovery sample

Data used in the discovery sample were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database [13]. ADNI was launched in 2003 with the primary goal of testing whether longitudinal magnetic resonance imaging (MRI), positron emission tomography (PET), and other serum or cerebrospinal fluid (CSF) biomarkers could serve as proxy markers for the progression of mild cognitive impairment (MCI) and early AD. After several waves of recruitment, ADNI has enrolled over 1000 individuals with AD, MCI, or with normal cognitive function. Detailed protocols for subject recruitment and biomarker accrual are available at the ADNI website (<http://www.adni-info.org/>).

In brief, subjects were recruited from over 50 sites across the United States and Canada and were measured longitudinally for changes in the brain measured through neuroimaging, biomarkers, and cognitive tests. At the time we accessed the ADNI database, there were 243 cognitively normal, 235 MCI, and 340 AD subjects in total. The subset of ADNI subjects analyzed for the discovery sample included 303 individuals of European descent who either had AD at baseline or converted to AD during follow-up and had cognitive data. Baseline data were defined as data from the examination with the first clinical diagnosis of AD. Seventeen individuals with age at onset younger than 60 years (indicative of familial AD) were excluded.

### 2.2. Replication sample

We selected the 65 most promising SNPs from the discovery sample on the basis of association with the outcome measure (see *Phenotypic measures*). These SNPs were evaluated for replication in an independent sample of 323 AD cases combined from the Religious Orders Study (ROS; 174 participants) and the Rush Memory and Aging Project (MAP; 149 participants). The ROS and MAP cohorts were developed and are managed by the same group of investigators at the Rush University Medical Center, and information about study design and data collection in these studies has been previously published [14,15]. In brief, subjects free of dementia were enrolled and followed annually for cognitive testing that is the same in both studies. We limited our analyses to subjects of European descent with a clinical diagnosis of AD after the age of 60.

### 2.3. Phenotypic measures

In ADNI, AD was defined as a participant meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria for probable AD [16]. Data were collected from participants with MCI at baseline and then at 6-month intervals up to 24 months, followed by a visit at 36 and at 48 months. Data were collected from participants with AD at baseline and then at 6, 12, and 24 months (no visit at 18 months or after 24 months, by design). Cognitive decline was measured based on longitudinally collected Alzheimer's Disease Assessment Scale–cognitive subscale (ADAS-cog) items. The ADAS-cog consists of 11 tasks measuring the disturbances of memory, language, praxis, attention, and other cognitive abilities, which are often referred to as the core symptoms of AD. ADAS-cog scores range from 0 to 70, with 0 indicating little or no cognitive impairment and 70 indicating severe cognitive impairment [17].

In the replication sample, we analyzed an independent composite measure of global cognition (GCOG) [18] based on 17 tests of cognition including immediate and delayed recall of the East Boston Story and Logical Memory II; immediate and delayed recall and recognition of a 10-item

word list; a 15-item Boston Naming Test; verbal fluency; 20-item form of the National Adult Reading Test; digit Span Forward and Backward; Digit Ordering; Number Comparison; the oral form of the Symbol Digit Modalities Test; judgment of line orientation; and Raven's Standard Progressive Matrices. Total scores of each of these tests were transformed into Z scores and GCOG was the average of those 17 Z scores.

#### 2.4. Genotyping and quality control

ADNI participants contributed blood samples from which DNA was extracted and genotyped using the Illumina Human Genome 610 Quad BeadChips. In the entire ADNI sample (cases and controls), 67 individuals were excluded because of a genotyped SNP call rate less than 98% and 17 individuals were excluded because the onset of their AD began at an age younger than 60 years. For analysis, we imputed the genotypes for all 1000 Genomes [19] SNPs using the Markov chain haplotyping software (MACH) [20] and retained those with pairwise linkage disequilibrium ( $r^2 > .80$ ) for further analysis. Imputed genotypes were analyzed as allele dosages adjusted by the quality of the imputation. SNPs were not analyzed if they had minor allele frequencies (MAF) of less than 3%. EIGENSTRAT [21] was used to measure principal components of ancestry (continuous measures summarizing genetic variation that were used to adjust for potential admixture in the sample).

For the ROS/MAP replication cohort, DNA was extracted from blood samples or frozen postmortem brain tissue and genotyped on the Affymetrix Genechip 6.0 platform as previously described [22]. Only self-declared non-Hispanic Caucasians were genotyped to minimize population heterogeneity. We applied standard quality control measures for subjects (genotype call rate  $>95\%$ , genotype-derived gender concordant with reported gender, excess inter/intraheterozygosity) and for SNPs (Hardy-Weinberg equilibrium  $P > .001$ ; MAF  $> 0.01$ , genotype call rate  $> 0.95$ ; misshap test  $> 1 \times 10^{-9}$ ) to these data. In all, 13 individuals were removed because of low SNP call rate. EIGENSTRAT [21] was subsequently used to identify and remove population outliers using default parameters. SNP genotypes were imputed using MACH software (version 1.0.16a) [23] and the 1000 Genomes (December 2010 release) reference panel. At the conclusion of the quality control pipeline and imputation, 203 ROS and 171 MAP subjects with AD diagnosis, longitudinal cognitive data ( $\geq 2$  evaluations), and quality-controlled genotyping were available for the replication analysis.

#### 2.5. Statistical analysis

We used linear regression models in the discovery cohort to test for genetic association with ADAS-cog. We included

every available postdiagnosis cognitive score in these models. The parameters of interest were the  $\beta$  coefficient and  $P$  values from an interaction term between the minor allele dosage at each SNP and the time in months since AD diagnosis. Conceptually, this interaction term tests whether SNP genotype is associated with a different effect of time on cognitive score. We used R version 2.10.0 to evaluate these models with generalized estimating equations to account for the intraindividual correlation in cognitive performance and genotype. Covariates such as *APOE*  $\epsilon 4$  allele count, education, age, gender, and prebaseline disease duration (for those who already had AD at baseline) were considered and retained in the final models if significant at a  $P$  value less than .05. We also included the first three principal components of ancestry in our final models. To limit the number of tests performed in the replication sample, we created a list of the 65 most promising SNPs on the basis of strength of statistical evidence for association, including supporting evidence from flanking SNPs.

In the replication sample, we used general linear mixed models to model GCOG decline over time, adjusted for age at AD diagnosis ( $P = .02$ ), years of education ( $P < .0001$ ), and sex ( $P = .0004$ ). From these models, we obtained estimated random slopes for each individual with at least two recorded measures of global cognition. Using these random slope estimates as outcomes, we then fit linear regression models using PLINK. Only postdiagnosis GCOG scores were used to compute the slopes.

Finally, we meta-analyzed the results from the discovery and replication samples using sample-size-weighted  $P$  values and the direction of the effect using METAL [24]. Associations were considered significant if  $P$  values were less than  $5 \times 10^{-8}$ .

### 3. Results

The discovery sample contained 303 AD cases, including 137 who converted during the study period from MCI to AD. The 166 individuals who were diagnosed with AD before the first study visit had a mean prebaseline disease duration of 3.3 years (SD = 2.6). Table 1 shows the baseline characteristics of the discovery and replication samples. The replication sample contained a higher percentage of females, had an older mean age at AD onset, and had a lower frequency of *APOE*  $\epsilon 4$  alleles.

Table 1  
Baseline characteristics of the discovery and replication samples

Variable	Percent or mean ADNI	Percent or mean ROS/MAP
Female	44%	70%
Age at onset (SD)	72.8 (7.6)	85.0 (6.4)
<i>APOE</i> $\epsilon 4$ positive (1 or 2 copies)	67%	39%
Years education (SD)	15.2 (3.0)	16.4 (3.6)




Fig. 1. Genome-wide association results for cognitive decline measured with ADAS-cog in the discovery sample. The y-axis shows the  $P$  values (on the  $-\log_{10}$  scale) for each association test. The x-axis is the chromosomal position of each SNP. The gold horizontal line at  $5 \times 10^{-8}$  indicates genome-wide significance. The inset shows the QQ plot for the adjusted  $P$  values.

Only sex and prebaseline disease duration were associated with rate of decline in ADAS-cog ( $P < .05$ ) and were retained as covariates, with males showing a slower rate of decline and individuals who had AD for a longer period before baseline showing more rapid decline. Figure 1 shows Manhattan and QQ plots for ADAS-cog in the discovery cohort. There was a significant genomic inflation factor ( $\lambda = 1.079$ ) for the interaction tests for rate of decline; all  $P$  values presented were adjusted




Fig. 2. Boxplots of ADAS-cog scores in rs11023139 minor allele carriers vs noncarriers. The line in each box represents the mean ADAS-cog score at each time point. The box heights indicate the interquartile range, and the whiskers extend to the most extreme datapoint, which is no more than 1.5 times the interquartile range.

accordingly. The strongest associations were with relatively rare (MAF = 3%) SNPs in and near the  $\alpha$ -mannosidase gene (*MAN2A1*) on chromosome 5 (109,230,839 bp,  $P = 1.0 \times 10^{-20}$ ). There were also associated variants in the spondin 1 (*SPON1*) gene on chromosome 11 (rs11023139,  $P = 7.0 \times 10^{-11}$ ), with minor alleles associated with slower progression (3.8 points per year in ADAS-cog). Figure 2 shows the mean ADAS-cog scores throughout the follow-up period for minor allele carriers versus noncarriers. We subsequently tested this SNP for association in the discovery sample with the rate of decline in other cognitive measures (the Rey Auditory Verbal Learning Test [RAVLT] and the Mini-Mental State Examination [MMSE]) and with the rate of amyloid  $\beta$ -40 ( $A\beta$ -40) and  $A\beta$ -42 accumulation in CSF.

The AD cases in the replication sample were followed for a mean of 2.5 years postdiagnosis (SD = 2.6 years). We compiled a list of 65 of the top SNP associations in ADNI of rate of decline among people with AD. Table 2 shows the results for these SNPs in the discovery sample. None of the 65 SNPs identified in the discovery sample trended toward association with rate of decline in GCOG in the replication sample at  $P$  values of .05 or less with the same effect direction. Although rs11023139 in *SPON1* was not significantly associated with a change in GCOG slope in ROS/MAP, a different SNP located 5.5 kb upstream did show evidence for association with the same effect direction (rs11606345,  $P = .002$ ). Although these SNPs are in complete linkage disequilibrium, the correlation between them is minimal ( $r^2 = .002$ ).

Finally, we evaluated whether or not there was an association with cognitive decline for all SNPs identified as significantly associated with AD at  $P$  values less than  $10^{-4}$  (Supplementary Table 5 in Naj et al [4]) in the recently published results from the Alzheimer Disease

Table 2  
Association results for ADAS-cog in ADNI

Chromosome	BP*	SNP	MAF <sup>†</sup>	SNP type <sup>‡</sup>	Gene	$\beta^§$	$P^¶$
1	171557600	<b>rs2421847</b>	0.04	Missense	<i>PRRC2C</i>	-0.26	8.71E-07
1	240605052	<b>rs12091371</b>	0.07	Intron	<i>FMN2</i>	-0.17	6.70E-08
2	14987571	NA	0.03	NA	NA	0.49	5.67E-07
2	16965493	NA	0.06	NA	NA	-0.28	1.29E-06
2	80281173	rs6738962	0.04	Intron	<i>CTNNA2</i>	-0.18	1.17E-08
2	128396167	rs78022502	0.06	3' UTR	<i>LIMS2</i>	-0.23	1.69E-06
3	39513278	rs538867	0.03	Intron	<i>MOBP</i>	-0.26	1.01E-07
3	51095028	rs9857727	0.1	Intron	<i>DOCK3</i>	-0.18	9.70E-06
3	165493136	rs2668205	0.03	Intron	<i>BCHE</i>	-0.27	9.63E-06
4	5237153	rs78647349	0.04	Intron	<i>STK32B</i>	-0.3	5.24E-07
4	87931404	rs340635	0.03	Intron	<i>AFF1</i>	-0.23	2.18E-07
5	55510656	<b>rs4700060</b>	0.1	Intron	<i>ANKRD55</i>	-0.21	1.07E-08
5	109111327	rs113689198	0.03	Intron	<i>MAN2A1</i>	-0.3	9.65E-09
5	109221026	rs112724034	0.03	NA	<i>PGAM5P1</i>	-0.31	8.51E-13
5	109230839	NA	0.03	NA	NA	-0.38	1.03E-20
5	110719187	rs77636885	0.03	Intron	<i>CAMK4</i>	-0.3	1.80E-06
5	118435127	rs116348108	0.04	Intron	<i>DMXL1</i>	-0.28	8.91E-07
5	126729450	rs143954261	0.04	Intron	<i>MEGF10</i>	-0.29	8.11E-07
5	127382302	rs146579248	0.04	NA	<i>FLJ33630</i>	-0.21	4.30E-07
5	153837106	rs148763909	0.03	3' UTR	<i>SAP30L</i>	-0.15	1.49E-08
6	78357637	NA	0.05	NA	NA	-0.29	8.97E-08
6	116056915	NA	0.04	NA	NA	-0.3	5.71E-08
6	124326227	rs117780815	0.03	Intron	<i>NKAIN2</i>	-0.31	6.28E-07
6	136288895	rs9494429	0.03	Intron	<i>PDE7B</i>	-0.23	5.97E-07
6	136368005	rs11154851	0.03	Intron	<i>PDE7B</i>	-0.25	1.14E-08
6	151102830	rs75253868	0.04	Intron	<i>PLEKHG1</i>	-0.26	2.24E-06
7	16707861	rs58370486	0.03	Intron	<i>BZW2</i>	-0.36	6.37E-11
7	16811139	rs73071801	0.04	Intron	<i>TSPAN13</i>	-0.33	9.97E-07
7	25161602	<b>rs1861525</b>	0.03	3' UTR	<i>CYCS</i>	-0.25	1.67E-07
7	37365196	<b>rs2392492</b>	0.04	Intron	<i>ELMO1</i>	-0.32	1.15E-06
7	43377276	rs17172199	0.08	Intron	<i>HECW1</i>	-0.28	1.09E-06
7	133747946	<b>rs11770757</b>	0.04	Intron	<i>EXOC4</i>	-0.16	4.76E-07
8	3088173	rs73660619	0.06	Intron	<i>CSMD1</i>	-0.26	7.45E-07
8	53214265	<b>rs7009219</b>	0.06	Intron	<i>ST18</i>	-0.16	5.12E-07
8	68761014	NA	0.05	NA	NA	-0.28	8.81E-09
9	132939792	rs4836694	0.11	Intron	<i>NCSI</i>	-0.21	7.15E-07
10	64635265	NA	0.04	NA	NA	-0.26	3.90E-10
10	122279476	rs118048115	0.04	Intron	<i>PPAPDC1A</i>	-0.34	6.41E-07
11	14224346	rs11023139	0.05	Intron	<i>SPON1</i>	-0.31	7.00E-11
11	14338703	rs61883963	0.06	Intron	<i>RRAS2</i>	-0.26	5.19E-07
11	14556220	rs34162548	0.05	Intron	<i>PSMA1</i>	-0.27	1.14E-06
11	37033930	NA	0.06	NA	NA	-0.16	8.22E-07
11	110499253	<b>rs326946</b>	0.17	Intron	<i>ARHGAP20</i>	-0.16	6.81E-07
11	128185570	NA	0.03	NA	NA	-0.31	8.92E-14
12	51878760	rs147845115	0.03	Intron	<i>SLC4A8</i>	-0.29	2.84E-07
12	94235165	rs61144803	0.04	Intron	<i>CRADD</i>	-0.16	5.02E-08
12	101221239	rs1399439	0.04	Intron	<i>ANO4</i>	-0.2	3.51E-07
13	61617648	NA	0.07	NA	NA	-0.24	2.83E-09
13	93945858	rs143258881	0.03	Intron	<i>GPC6</i>	-0.29	6.73E-08
13	109473946	rs17393344	0.06	Intron	<i>MYO16</i>	-0.26	1.69E-08
14	95764564	rs115102486	0.03	Intron	<i>CLMN</i>	-0.31	2.28E-08
15	27712644	rs74006954	0.03	Intron	<i>GABRG3</i>	-0.28	2.74E-07
15	58730639	rs17301739	0.07	Intron	<i>LIPC</i>	-0.28	1.45E-06
16	24675589	rs8045064	0.05	NA	<i>FLJ45256</i>	-0.21	4.27E-08
16	77876763	rs9934540	0.03	Intron	<i>VAT1L</i>	-0.25	3.55E-07
17	45888374	rs62076103	0.07	Intron	<i>OSBPL7</i>	-0.26	3.32E-07
17	45905622	rs62076130	0.06	Intron	<i>MRPL10</i>	-0.26	7.82E-07
17	45930539	rs4794202	0.08	Intron	<i>SP6</i>	-0.19	7.99E-08
17	47134762	NA	0.03	NA	NA	-0.3	6.07E-11
17	48692082	rs117964204	0.04	Intron	<i>CACNA1G</i>	-0.28	9.44E-10
17	59292436	rs72832584	0.05	Intron	<i>BCAS3</i>	-0.3	1.14E-11
19	51422877	NA	0.05	NA	NA	-0.34	3.00E-10

(Continued)



Table 2  
Association results for ADAS-cog in ADNI (Continued)

Chromosome	BP*	SNP	MAF <sup>†</sup>	SNP type <sup>‡</sup>	Gene	$\beta$ <sup>§</sup>	$P$ <sup>¶</sup>
19	51430596	<b>rs7245858</b>	0.04	Missense	<i>LOC390956</i>	-0.28	2.03E-06
20	2384972	rs34972666	0.11	Intron	<i>TGM6</i>	-0.23	3.46E-08
22	44526105	rs75617873	0.03	Intron	<i>PARVB</i>	-0.17	5.01E-07

Abbreviations: NA, not available; UTR, untranslated region.

NOTE: SNPs in bold were genotyped.

\*BP indicates base pair location in release 19, build 135 of the human genome in the dbSNP database.

<sup>†</sup>Minor allele frequency in ADNI.

<sup>‡</sup>Type of SNP.

<sup>§</sup>Change in ADAS-cog per copy of the minor allele per month with AD, in which positive numbers indicate more rapid decline and negative numbers indicate slower decline.

<sup>¶</sup> $P$  value after correction for a genomic inflation factor of 1.079.

Genetics Consortium (ADGC) study, which contains more than 19,490 AD cases and 36,770 controls. Five of the 447 AD-associated SNPs selected in this manner were associated with rate of decline in ADAS-cog at a significance level  $P$  value less than .05 in the discovery sample. The minor alleles for a SNP in the poliovirus receptor-related 2 gene (*PVLR2*) (rs440277,  $P = .003$ ) were associated with a lower risk of developing AD and a slower rate of decline, as was a SNP in the CD33 antigen gene (*CD33*) (rs1354106,  $P = 0.04$ ). However, in the replication sample, there were three SNPs near the gene gap junction protein, beta 5 (*GJB5*), which were associated with GCOG. The strongest effect was from rs12048230 ( $P = 1.9 \times 10^{-7}$ ) and was associated with a slower rate of decline and lower risk of AD in the ADGC samples.

#### 4. Discussion

This study is the first to search for and discover unbiased associations between genome-wide genetic variants and rate of cognitive decline in AD cases. Although the sample size was small, several intriguing candidate genes were identified. The most interesting candidate gene we identified is *SPON1*, because variants were significantly associated in the discovery and replication cohort and because of its biological plausibility. The protein SPON1 binds the central terminal domain of the amyloid precursor protein (APP) and inhibits its cleavage by the  $\beta$ -secretase complex (BACE) [25]. Although all of the common ( $MAF > 3\%$ ) associated SNPs in *SPON1* are intronic, there is a rare ( $MAF = 1\%$ ) missense mutation that is strongly associated with rate of decline. The most significantly associated SNP in the gene was also associated (much less significantly) with slower rate of decline in the RAVLT ( $P = .008$ ) and the MMSE ( $P = .003$ ), and the same SNP was associated with a slower rate of A $\beta$ -40 (but not A $\beta$ -42) accumulation in CSF ( $P = .001$ ).

Several of the other significant association results are in genes with functions relevant to neuronal maintenance and neurotransmission, including exocyst complex component 4 (*EXOC4*), gamma-aminobutyric acid receptor gamma-3 (*GABRG3*), and vesicle amine transport protein 1 homolog (*VAT1L*), and many involved in calcium signaling and

homeostasis, including calcium/calmodulin-dependent protein kinase IV (*CAMK4*), neuronal calcium sensor 1 (*NCS1*), and voltage-dependent calcium channel alpha 1G subunit (*CACNA1G*). Other notable candidates for association with variable rate of decline in AD patients are involved in neuronal apoptosis signaling, including engulfment and cell motility protein 1 (*ELMO1*) and somatic cytochrome C (*CYCS*), whereas hepatic lipase (*LIPC*) [26] and oxysterol binding protein-like 7 (*OSBPL7*) are involved in lipid homeostasis [26].

Our results require confirmation in larger datasets, but they support the intriguing possibility that previously unknown genetic variants may influence the rate of decline in AD. Larger cohorts with longitudinal data, providing improved statistical power, are being collected to provide more definitive replication.

The strengths of this analysis were the unbiased nature of the GWAS, a discovery and a replication sample, and a statistical model that allowed us to specifically measure test for a differential rate of decline (rather than cognitive function in general) while maximizing the information content of the data (use of repeated measures). Our study was limited by small sample sizes in both datasets and by the fact that the phenotype of cognitive decline was measured and analyzed differently in the discovery and replication cohorts. A full description of these differences is beyond the scope of this paper, but there is face validity to the assumption that both represent a general measure of overall cognitive ability because the ADAS-Cog and the GCOG incorporate measures on various cognitive domains. Our experience with the ADNI data indicates that the genetic association tests for decline are highly sensitive to the assessment scale used.

One of the previous candidate gene studies of rate of decline in AD cases identified SNP rs1868402 in a gene that encodes the regulatory subunit of protein phosphatase B (*PPP3R1*) that was not associated with risk for AD or age at onset, but it was associated with rate of decline as measured by the Clinical Dementia Rating Sum of Boxes (CDR-SB) and tau phosphorylated at threonine 181 (ptau<sub>181</sub>) levels measured in CSF, a known biomarker for AD [12]. The other candidate gene study found two SNPs (rs3746319, rs8192708) associated with global cognition,

one the zinc finger protein 224 gene (*ZNF224*) and one in the gene encoding phosphoenolpyruvate carboxykinase (*PCK1*) [11]. Examining these three SNPs, we found a trend toward association with ADAS-cog for rs1868402 ( $P = .14$ ) in the same direction as the previous report [12]. The significant results in that study were generated under a dominant model and only in individuals with low levels of A $\beta$ -42 in CSF. Given the different phenotypes, subsets of the ADNI data, and statistical and genetic models used for analysis across these studies, the trend toward replication in this analysis substantially increases the evidence that *PPP3R1* variants may mediate AD progression through pathways related to ptau<sub>181</sub>. In the study presented here, there was also a trend toward association with rs3746319 ( $P = .08$ ) but not rs8192708 with change in ADAS-cog.

In summary, we utilized a discovery sample and a replication sample to perform the first genome-wide study to assess genetic variants associated with cognitive rate of decline in people with AD. We identified several SNPs with statistical evidence in genes that have not been previously associated with AD risk, most notably *SPONI*, which may contain variants of which minor alleles slow disease progression by lowering the amount of extracellular A $\beta$ -40. A different, nearby SNP was associated with decline in an independent sample using a different measure of cognition. Novel genetic associations with rate of decline in AD may provide new insights into the pathophysiology of AD and new targets for therapeutic development.

### Acknowledgments

Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database ([adni.loni.ucla.edu](http://adni.loni.ucla.edu)). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at [http://adni.loni.ucla.edu/wp-content/uploads/how\\_to\\_apply/ADNI\\_Acknowledgement\\_List.pdf](http://adni.loni.ucla.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf).

Data collection and sharing for this project was funded by ADNI (National Institutes of Health [NIH] Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfis Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec, Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck &

Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ([www.fnih.org](http://www.fnih.org)). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California–San Diego. ADNI data are disseminated by the Laboratory for NeuroImaging at the University of California–Los Angeles. This research was also supported by NIH grants P30 AG010129, K01 AG030514, and the Dana Foundation. This research was supported by grants HG02213 and AG027841 (R.C.G.) from NIH and a Mentored New Investigator Grant from the Alzheimer's Association (R.S./R.C.G.). This research was also supported in part by the Alzheimer's Disease Genetics Consortium, NIH grant U01 AG032984 (Gerard D. Schellenberg, PI).

### RESEARCH IN CONTEXT

1. Systematic review: The authors have directly participated in several studies and consortia dealing with the cognitive decline associated with AD and normal aging. As such, they have direct knowledge of and participation in much of the previous body of research on cognitive change. They also conducted a thorough literature search to identify other projects with similar goals.
2. Interpretation: This research represents the first GWAS to search for genetic variants affecting disease trajectory in AD cases. Previous efforts have included a mixture of cognitively normal participants, AD cases, and individuals with non-AD dementias. As such, this research has provided the first evidence that novel genetic variants (not variants previously associated with AD risk in general) contribute to the variability in disease trajectory.
3. Future directions: This project was done in a relatively small sample of AD cases; thus, the results must be considered as preliminary. However, we have learned valuable lessons about cognitive testing and the genetic architecture of AD-associated decline, and efforts are currently underway to conduct these analyses in much larger samples and to better harmonize the various cognitive tests used across datasets. In the future, we hope to identify novel biological pathways involved in AD progression and potential treatment targets within those pathways.

## References

- [1] Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet* 2009;41:1088–93.
- [2] Lambert J, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet* 2009;41:1094–9.
- [3] Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. *JAMA* 2010;303:1832–40.
- [4] Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buross J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nat Genet* 2011;43:436–41.
- [5] Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet* 2011;43:429–35.
- [6] Wilson R, Leurgans S, Boyle P, Schneider J, Bennett D. Neurodegenerative basis of age-related cognitive decline. *Neurology* 2010;75:1070–8.
- [7] Verdelho A, Madureira S, Moleiro C, Ferro JM, Santos CO, Erkinjuntti T, et al. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. *Neurology* 2010;75:160–7.
- [8] Kume K, Hanyu H, Sato T, Hirao K, Shimizu S, Kanetaka H, et al. Vascular risk factors are associated with faster decline of Alzheimer disease: a longitudinal SPECT study. *J Neurol* 2011;258:1295–303.
- [9] Menkes D, Buchman A, Shah R, Boyle P, Bennett D. Kidney function is associated with the rate of cognitive decline in the elderly. *Neurology* 2010;74:1656–7.
- [10] Boyle P, Buchman A, Wilson R, Leurgans S, Bennett D. Association of muscle strength with the risk of Alzheimer disease and the rate of cognitive decline in community-dwelling older persons. *Arch Neurol* 2009;66:1339–44.
- [11] Shulman J, Chibnik L, Aubin C, Schneider J, Bennett D, De Jager P. Intermediate phenotypes identify divergent pathways to Alzheimer's disease. *PLoS One* 2010;21:e11244.
- [12] Cruchaga C, Kauwe J, Mayo K, Spiegel N, Bertelsen S, Nowotny P, et al. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. *PLoS Genet* 2010;6:e1001101.
- [13] Weiner MW, Aisen PS, Jack CR Jr, Jagust WJ, Trojanowski JQ, Shaw L, et al. The Alzheimer's Disease Neuroimaging Initiative: progress report and future plans. *Alzheimers Dement* 2010;6:202–11. e207.
- [14] Bennett D, Schneider J, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. *Neurology* 2006;66:1837–44.
- [15] Bennett D, Schneider J, Buchman A, Mendes de Leon C, Bienias J, Wilson R. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. *Neuroepidemiology* 2005;25:163–75.
- [16] McKhann GM, Drachman D, Folstein MF, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group. *Neurology* 1984;34:939–44.
- [17] Rosen W, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. *Am J Psychiatry* 1984;141:1356–64.
- [18] Wilson RS, Beckett LA, Barnes LL, Schneider JA, Bach J, Evans DA, et al. Individual differences in rates of change in cognitive abilities of older persons. *Psychol Aging* 2002;17:179–93.
- [19] The 1000 Genomes Project; A map of the human genome variation from population-scale sequencing. *Nature* [1061–1073]. Available at: [www.1000genomes.org](http://www.1000genomes.org), 467.
- [20] Li M, Boehnke M, Abecasis G. Efficient study designs for test of genetic association using sibship data and unrelated cases and controls. *Am J Hum Genet* 2006;78:778–92.
- [21] Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* 2006;38:904–9.
- [22] Chibnik L, Shulman J, Leurgans S, Schneider JA, Wilson RS, Tran D, et al. CR1 is associated with amyloid plaque burden and age-related cognitive decline. *Ann Neurol* 2011;69:560–9.
- [23] Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genet Epidemiol* 2010;34:816–34.
- [24] Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 2010;26:2190–1.
- [25] Ho A, Sudhof TC. Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage. *Proc Natl Acad Sci U S A* 2004;101:2548–53.
- [26] Cai SJ, Wong DM, Chen SH, Chan L. Structure of the human hepatic triglyceride lipase gene. *Biochemistry* 1989;28:8966–71.

# Did you know?

The screenshot shows the homepage of the journal *Alzheimer's & Dementia*. At the top, there is a search bar with a dropdown menu set to 'This Periodical'. Below the search bar, there are links for 'Advanced Search', 'MEDLINE', 'My Recent Searches', 'My Saved Searches', and 'Search Top'. The main content area features a 'Current Issue' section for November 2008, Vol. 5, No. 8, which is noted as 'Now Included on MEDLINE'. A 'Featured Article' section lists several topics: 'Cognitive performance and informant reports in the diagnosis of cognitive impairment and dementia in African Americans and whites', 'Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging', 'Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease', 'The incidence of cognitive symptoms in Alzheimer's disease', and 'Evidently technologies for Alzheimer's disease care: Research findings, directions, and challenges'. On the left side, there is a sidebar with navigation links such as 'JOURNAL HOME', 'CURRENT ISSUE', 'ARTICLES IN PRESS', 'SEARCH THE JOURNAL', 'JOURNAL INFORMATION', 'ALZHEIMER'S ASSOCIATION', 'CONTACT US', and 'SUBSCRIBE TO JOURNAL'. At the bottom, there is a 'STAArt' logo and a 'JOIN' button.

You can search  
**Alzheimer's  
 & Dementia** and  
 400 top medical  
 and health  
 sciences journals  
 online, including  
**MEDLINE.**

Visit [www.alzheimersanddementia.org](http://www.alzheimersanddementia.org) today!